Is Leap Therapeutics Inc (LPTX) a Stock to Watch After Gaining 57.05% This Week?

Overall market sentiment has been high on Leap Therapeutics Inc (LPTX) stock lately. LPTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Leap Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPTX!

See Full LPTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With LPTX Stock Today?

Leap Therapeutics Inc (LPTX) stock has risen 18.36% while the S&P 500 is lower by -0.21% as of 1:23 PM on Tuesday, Nov 21. LPTX has risen $0.38 from the previous closing price of $2.07 on volume of 392,902 shares. Over the past year the S&P 500 has gained 14.88% while LPTX is lower by -58.47%. LPTX lost -$5.72 per share in the over the last 12 months. To screen for more stocks like Leap Therapeutics Inc click here.

More About Leap Therapeutics Inc

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205. Click Here to get the full Stock Report for Leap Therapeutics Inc stock.